The antiviral disables RNA replication machinery in MERS and SARS viruses. Can it beat back SARS-CoV-2?

Under careful watch of the World Health Organization, doctors will test a range of COVID-19 therapies, including HIV and flu antivirals, blood plasma infusions, and traditional Chinese medicines.

Combining the medications improved conditions in patients with severe 2019-nCoV infections, say doctors in Thailand.

This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.

Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug.

REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.

A new study finds that more than 200 human-targeted, non-antibiotic drugs inhibit the growth of bacterial species that make up part of the human microbiome.

One dose of the medication, called Xofluza, cripples influenza by interfering with an enzyme critical for viral replication.  

T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections.